Get started
Author

Abdullah M. Alrajhi

Observed names: A M. Alrajhi, A. Alrajhi, Abdullah M. Alrajhi, Abdullah Alrajhi, Abdullah M Alrajhi, Abdullah M. AlRajhi, Abdullah Mohammad Alrajhi
Observed institutions: Alfaisal University, King Saud bin Abdulaziz University for Health Sciences, Umm al-Qura University, King Fahd Medical City, King Saud University, King Abdulaziz Medical City, MelroseWakefield Healthcare, Ministry of Health, King Abdullah Medical City
ORCID: 0000-0001-9522-9446
Observed ORCID: 0000-0001-9522-9446
OpenAlex ID: A5045917232
Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer
2018 · Maryann R. Cooper, Abdullah M. Alrajhi, et al. · American Journal of Therapeutics · 14
Use of Thrombopoietin Receptor Agonists in Pregnancy
2021 · Jude Howaidi, Abdullah M. AlRajhi, et al. · Hematology/Oncology and Stem Cell Therapy · 13
PDF
Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature
2025 · Fahad Alshammari, Abdullah M. Alrajhi, et al. · Hematology · 10
The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report
2019 · Abdullah M. Alrajhi, Sarah A. Alhazzani, et al. · BMC Pregnancy and Childbirth · 9
Bleomycin Induced Lung Toxicity in Hodgkin Lymphoma Patients Treated with ABVD Regimen- a Single Center Experience from Riyadh, Saudi Arabia
2024 · Alaa Eldein Yahia, Abdullah Alsakkaf, et al. · Blood · 4
Assessment of cardio-oncology knowledge and practice among healthcare providers in Saudi Arabia: a comprehensive nationwide survey
2024 · Hisham A. Badreldin, Nada Alsuhebany, et al. · Cardio-Oncology · 3
PDF
Comparative Assessment of Drug Lag for Approved Oncology Targeted Therapies Between Saudi Arabia, the United States, and the European Union
2024 · Mohammed Alnuhait, Abdullah Alshammari, et al. · Therapeutic Innovation & Regulatory Science · 3
De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion
2022 · Maha Hameed, Mohammed Alnoamani, et al. · Hematology · 3
Tacrolimus-Induced Diffuse Coronary Artery Spasm
2022 · Abadil Samer, Fahad Almehmadi, et al. · Cureus · 3
PDF
Parenteral Nutrition Management from the Clinical Pharmacy Perspective: Insights and Recommendations from the Saudi Society of Clinical Pharmacy
2026 · Nora Albanyan, Dana Altannir, et al. · Pharmacy · 2
PDF
Pegasparaginase-induced hepatotoxicity in patients with acute lymphocytic leukemia in the Saudi population: A retrospective cohort study
2026 · Ghadah H. Alshehri, Nada Alsuhebany, et al. · Medicine · 2
Validation of the HFA-ICOS cardiovascular toxicity risk tool in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors: Real-world data from the Saudi population.
2025 · Nada Alsuhebany, Hamad Alkhalaf, et al. · Journal of Clinical Oncology · 2
Clinical features and outcomes of newly diagnosed classical Hodgkin lymphoma patients in Saudi Arabia: a multicenter cohort study
2025 · Mai Alalawi, Abdullah M. Alrajhi, et al. · Scientific Reports · 2
PDF
Quality of life for patients on oncology treatments in the Kingdom of Saudi Arabia: a systematic review
2025 · Abdullah U. Althemery, Rawan Alzahrani, et al. · Journal of Pharmaceutical Policy and Practice · 2
PDF
Bv-AVD Esclation after Partial Response to ABVD Chemotherapy in Patinets with HL: A Retrospective Study
2024 · Amani Almuqbil, Abdullah Alrajhi, et al. · Blood · 2
Prognostic Value of Interim PET/CT in Predicting Outcomes of Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP Therapy: A Retrospective Analysis from Single Centre, Riyadh, Saudi Arabia
2024 · Asim A Alharbi, Abdullah Alsakkaf, et al. · Blood · 2
PDF
Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment Free Remission (TFR) in Chronic Myeloid Leukemia: Successful Achievement of TFR in More Than Two-Third of Patients in a Real-World Practice
2024 · Aamer Aleem, Naila A. Shaheen, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
PDF
Revitalizing oncology medications access in Saudi Arabia: Current challenges and recommendations by the Saudi Oncology Pharmacy Assembly
2024 · Nora Alkhudair, Jude Howaidi, et al. · Journal of Oncology Pharmacy Practice · 2
Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects
2023 · Abdullah AlZahrani, Nada Alsuhebany, et al. · Hematology · 2
PDF
Implementing Oncology Pharmacy Boot Camp for Advanced Pharmacy Practice Experience Students at a Regional Conference in Saudi Arabia
2023 · Mohammed Alnuhait, Atika Alharbi, et al. · Cureus · 2
PDF
Safety and Efficacy of Azacitidine with Venetoclax for Newly Diagnosed Intensive Chemotherapy Ineligible, and Relapsed or Refractory Acute Myeloid Leukemia in Arab Population: A Single-Center, Retrospective Study
2021 · Mohammmad Alwadi, Jude Howaidi, et al. · Blood · 2
Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study)
2025 · Ayman Alhejazi, Ahmad Alhuraiji, et al. · Frontiers in Oncology · 1
PDF
Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review
2025 · Alaa Eldein Yahia, Ibrahim Motabi, et al. · Leukemia Research Reports · 1
Clinical Relevance of Therapeutic Drug Monitoring of Busulfan-Based Regimens in Adult Hematopoietic Stem Cell Transplant Patients
2024 · Rakan Jamal Alanazi, Abdullah Mohammad Alrajhi, et al. · Archives of Pharmacy Practice · 1
PDF
Blinatumomab with Tyrosine Kinase Inhibitor for Ph-Positive B-Acute Lymphoblastic Leukemia (B-ALL): Multicenter Retrospective Review
2023 · Manar Aleid, Abdullah Alrajhi, et al. · Blood · 1
PDF
Works count: 53
Citation count: 93
H-index: 4
I10-index: 3
Year
Topic
Type